Replidyne Orapem Antibiotic Likely To Need Additional Trials Before Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Replidyne is conducting an additional Phase III trial of its oral beta-lactam antibiotic Orapem in anticipation of an FDA request for additional studies, according to the firm’s initial public offering prospectus.